Bundle & Save
Over 30%
Add items to unlock rewards.
Free
shipping
$19.95 per item
20%
off
$15.96 per item
25%
off
$14.96 per item
32% off
+ free
gift
$13.56 per item

Research news · menopause care

Hot flashes treatment guidelines: what the American College of Physicians recommended

New hot flashes treatment guidelines from the American College of Physicians (ACP), published Oct 6, 2026 in Annals of Internal Medicine, rank medicines for hot flashes and night sweats (vasomotor symptoms). A Nov 12, 2026 U.S. Medicine report summarized the ladder: hormone therapy first, then certain other medicines if hormones are not suitable. This page is a plain-language summary of that reporting. It is not personal treatment advice, and an antiperspirant does not treat hot flashes.

Hot flashes treatment guidelines at a glance

  • ACP says vasomotor symptoms affect up to 80% of women in perimenopause and can last into the mid-60s or early 70s (U.S. Medicine; ACP guideline).
  • First line (strong recommendation): estrogen plus a progestogen if you have a uterus, or estrogen alone if you do not. Second line: desvenlafaxine or venlafaxine. Third line: escitalopram or paroxetine, gabapentin, or elinzanetant or fezolinetant.

The evidence base

What the hot flashes treatment guidelines were based on

A companion systematic review by Diem and colleagues, also in Annals of Internal Medicine, included 90 randomized trials of at least eight weeks, with searches through March 3, 2026. U.S. Medicine reports that evidence certainty was low to moderate for most comparisons, that most trials were short-term, and that long-term harms data are limited. VA clinicians co-authored the work. We read the U.S. Medicine article in full and the guideline only at abstract/snippet level.

Value and limits

Other points in the hot flashes treatment guidelines

U.S. Medicine reports that estrogens with or without a progestogen were judged high economic value, while fezolinetant was judged low value. The panel said clinicians should use informed decision-making and discuss benefits, harms, contraindications, other conditions, preferences, cost and access. It also said more evidence is needed for people who cannot use hormone therapy and for newer nonhormonal agents.

FAQ

Hot flashes treatment guidelines: quick answers

What do the hot flashes treatment guidelines recommend first?
ACP’s strong first-line recommendation is menopausal hormone therapy: estrogen with a progestogen for women with a uterus, or estrogen alone for women without a uterus, based on high-certainty evidence as described in the U.S. Medicine summary.
What if hormones are not an option under these hot flashes treatment guidelines?
ACP’s second-line suggestion is desvenlafaxine or venlafaxine (moderate-certainty evidence). Third-line suggestions include escitalopram or paroxetine, gabapentin, or the neurokinin receptor antagonists elinzanetant or fezolinetant. Those are conditional recommendations. A clinician has to judge what is appropriate for you.
Do hot flashes treatment guidelines mean I should start a medicine from this page?
No. Guidelines inform clinicians. They are not a personal treatment plan or a substitute for a visit. Do not start, stop or change a medicine based on this summary.
Do hot flashes treatment guidelines say an antiperspirant treats hot flashes?
No. These guidelines are about medicines for vasomotor symptoms. An underarm antiperspirant can reduce underarm wetness; it does not treat hot flashes or night sweats. Maxim makes no such claim.
How strong is the evidence behind these hot flashes treatment guidelines?
U.S. Medicine reports low-to-moderate certainty for most comparisons, short-term trials, limited harms data and little head-to-head comparison. The review also found that some medicines reduced how often symptoms occurred but not how severe they were.

What the systematic review behind the hot flashes treatment guidelines found

Compared with placebo, the review reported that estrogens with or without progestogens, conjugated estrogen with bazedoxifene, and oxybutynin reduced both frequency and severity of vasomotor symptoms. Neurokinin receptor antagonists, SNRIs, SSRIs, gabapentin and progestogens reduced frequency but not severity, according to the U.S. Medicine summary. Estrogen effect varied by dose but not by route. Estrogens, neurokinin receptor antagonists, SNRIs and SSRIs improved menopause-related quality of life; several non-estrogen options improved sleep quality. Few serious adverse events were reported in the trials, but the studies were not designed to assess long-term harms and observational studies of long-term harms were not included.

Limits of this hot flashes treatment guidelines summary

We read the free U.S. Medicine news article in full. We did not read the complete Annals guideline or the full systematic review. Details, caveats and dosing discussion that appear only in those papers are not included here. This page cannot tell you which option, if any, is right for you.

Hot flashes treatment guidelines do not cover underarm sweating

Vasomotor symptoms are not the same as ordinary underarm sweating. For related Maxim pages, see menopause hot flashes and night sweats guidance and menopause night sweats vs underarm sweating.

Sources

  1. Mooney B. New Guidelines Endorse Specific Pharmacologic Treatments for Menopausal Vasomotor Symptoms. U.S. Medicine, Nov 12, 2026 (full news article read).
  2. Qaseem A, Mackey K, Yost J, Shekelle PG, Shamliyan TA, Cross JT Jr; Clinical Guidelines Committee of the American College of Physicians. Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2026 Oct 6. doi: 10.7326/ANNALS-26-01205 (PMID 42832802). Abstract/snippet only; full guideline not reviewed.
  3. Diem S, Landsteiner A, Langsetmo L, et al. Pharmacologic Treatments for Female Menopausal Vasomotor Symptoms: A Systematic Review and Meta-analysis for the American College of Physicians. Ann Intern Med. 2026 Oct 6. doi: 10.7326/ANNALS-26-00943 (PMID 42832800). Findings summarized from the U.S. Medicine report.

Educational information, not a diagnosis or medical advice. Sources were opened and read on Nov 13, 2026. This summary is not evidence for any Maxim product and is not a treatment plan.

Questions about these hot flashes treatment guidelines?

Talk with a clinician who can review your history, risks and preferences. Do not start or stop a medicine based on this page.

The treatment ladderRead the sources

Educational information only, not medical advice. The guideline did not test Maxim, and Maxim makes no claim to treat hot flashes, night sweats or menopause.